Anupam Rasayan India Limited — PPTs, 23-05-2026: Investor Presentation

Anupam Rasayan is acquiring a controlling stake in Bliss GVS Pharma, a well-established pharmaceutical formulations company known for its branded products across 50+ therapeutic segments. Bliss GVS holds strong global accreditations, including US FDA and EU GMP approvals.

**Business Performance:** Bliss GVS's revenue grew from 752 Cr in FY23 to 927 Cr in FY26, with PAT increasing from 77 Cr to 135 Cr. The company is financially robust, holding 167 Cr in cash with zero net debt as of March 2026.

**Growth Drivers:** This acquisition opens up significant growth avenues. Anupam plans to leverage Bliss GVS's substantial pipeline of 62+ molecules and current low capacity utilization (30%) to expand into regulated markets like the USA and Europe. Strategic synergies include entering new therapeutic areas such as cardiovascular and antidiabetic segments, and boosting its CDMO business.

**Recent Developments:** Bliss GVS has recently completed significant capex projects totaling over 350 Cr, enhancing its manufacturing footprint and diversifying dosage capabilities, alongside securing US FDA approval for its Palghar suppository unit.

**Outlook:** This strategic move positions Anupam for diversified growth, strengthened market presence in high-barrier segments, and benefits from vertical integration.